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 ABSTRACT 
 Background In an integrated overview of the benefi ts and risks of menopausal hormone therapy (HT), the 
Women ’ s Health Initiative (WHI) investigators have claimed that their  ‘ fi ndings  … do not support use of 
this therapy for chronic disease prevention ’ . In an accompanying editorial, it was claimed that  ‘ the WHI 
overturned medical dogma regarding menopausal [HT] ’ . 
 Objectives To evaluate those claims. 
 Methods Epidemiological criteria of causation were applied to the evidence. 
 Results A  ‘ global index ’ purporting to summarize the overall benefi t versus the risk of HT was not valid, 
and it was biased. For coronary heart disease, an increased risk in users of estrogen plus progestogen (E    P), 
previously reported by the WHI, was not confi rmed. The WHI study did not establish that E   P increases 
the risk of breast cancer; the fi ndings suggest that unopposed estrogen therapy (ET) does not increase the 
risk, and may even reduce it. The fi ndings for stroke and pulmonary embolism were compatible with an 
increased risk, and among E   P users there were credible reductions in the risk of colorectal and endometrial 
cancer. For E   P and ET users, there were credible reductions in the risk of hip fracture. Under  ‘ worst case ’ 
and  ‘ best case ’ assumptions, the changes in the incidence of the outcomes attributable to HT were minor. 
 Conclusions Over-interpretation and misrepresentation of the WHI fi ndings have damaged the health and 
well-being of menopausal women by convincing them and their health professionals that the risks of HT 
outweigh the benefi ts. 
 INTRODUCTION 
 The Women ’ s Health Initiative (WHI) investigators 1 have 
published an integrated overview of data regarding meno-
pausal hormone therapy (HT) derived from two randomized, 
 ‘ double-blind ’ , controlled trials that commenced in 1993 
(intervention phase), and from follow-up data collected after 
the trials were terminated (post-intervention phase). In one 
trial, women with an intact uterus were assigned to conjugated 
equine estrogen (0.625 mg/day) plus medroxyprogesterone 
acetate (2.5 mg/day) ( ‘ estrogen plus progestogen ’ , E    P) 
or placebo, and the trial was terminated after a median of 5.6 
years of follow-up; in the second trial, hysterectomized women 
were assigned to conjugated equine estrogen (0.625 mg/day) 
without an added progestogen ( ‘ estrogen therapy ’ , ET) or 
placebo, and the trial was terminated after 7.2 years of 
follow-up. In both trials, cumulative follow-up in the combined 
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 The investigators concluded that  ‘ fi ndings  … in the two 
WHI [HT] trials do not support use of this therapy for chronic 
disease prevention, although it is appropriate for symptom 
management in some women ’ . In an accompanying editorial 2 , 
the fi ndings were described as  ‘ a victory for women and their 
health ’ , and it was claimed that  ‘ the WHI overturned medical 
dogma regarding menopausal [HT] ’ . In this commentary, we 
evaluate those claims. 
 SUMMARY OF THE WHI FINDINGS 
 The primary endpoints specifi ed in the WHI study were 
coronary heart disease (CHD) and invasive breast cancer. 
Hazard ratios (HRs) for those outcomes, together with 
other selected endpoints (stroke, pulmonary embolism, 
colorectal cancer, endometrial cancer, hip fracture, and 
all-cause mortality) were combined to yield what was 
designated as a  ‘ global index ’ ,  ‘ summarizing the balance 
of risks and benefi ts’ 3 . A large number of secondary end-
points, selected secondary endpoints, and self-reported 
endpoints were also studied. Here we focus on the 
results in the intervention phase and in the total cumulative 
follow-up data for the primary endpoints of CHD and 
breast cancer, and on the other components of the global 
index. 
 HRs for the primary endpoints of CHD and breast cancer, 
and for the global index are given in Table 1. For E   P users, 
the 95% confi dence intervals (CIs) around the HRs excluded 
1.00 for breast cancer (intervention phase, 1.24; cumulative 
follow-up, 1.28) and the global index (intervention 
phase, 1.12). For ET users, the HR for breast cancer was 
0.79 (cumulative follow-up). 
 HRs for constituents of the global index (other than the 
primary endpoints) for which the 95% CIs around the HRs 
excluded 1.00 are given in Table 2. For E   P users, in the 
intervention phase the HRs were signifi cantly elevated for 
stroke (HR 1.37) and pulmonary embolism (1.98), and 
reduced for colorectal cancer (0.62) and hip fracture (0.67); 
in the cumulative data, the HRs were reduced for endometrial 
cancer (0.67) and hip fracture (0.81). For ET users, in the 
intervention phase the HR was increased for stroke (1.35) 
and reduced for hip fracture (0.67). 
 Estimated absolute risks (incidence rates in the non-exposed 
women subtracted from the rates in the exposed women) are 
given in Table 3. For E   P users, in the intervention phase 
the absolute risks ranged from 6 per 10 000 women per 
year (colorectal cancer; hip fracture) to 20 per 10 000 women 
per year (global index); in the cumulative follow-up data, the 
range was 5 (hip fracture) to 12 (global index). For ET users, 
in the intervention phase the range was 7 (breast cancer) to 
11 (stroke); in the cumulative data, it was 2 (hip fracture) 
to 5 (stroke). 
 EVALUATION 
 Below we apply relevant epidemiological criteria of causation 
(or prevention) 4-7 to the WHI evidence. The criteria are inter-
related and, when appropriate, we cross-refer. But fi rst, we 
consider the global index, which on conceptual grounds must 
be rejected in its entirety. 
 Table 1 Women ’ s Health Initiative: hazard ratios for intervention phase and cumulative follow-up 
of 13 years 
 Outcome  Exposed/controls  Hazard ratio  95% confi dence interval 
 E   P/placebo 8506/8102
Intervention phase
  coronary heart disease 196/159 1.18 0.95 – 1.45
  breast cancer 206/155 1.24 1.01 – 1.53
  global index 876/736 1.12 1.02 – 1.24
Cumulative follow-up
  coronary heart disease 487/430 1.09 0.96 – 1.24
  breast cancer 434/323 1.28 1.11 – 1.48
  global index 2198/1997 1.06 1.00 – 1.13
 ET/placebo 5310/5429
Intervention phase
  coronary heart disease 204/222 0.94 0.78 – 1.14
  breast cancer 104/135 0.79 0.61 – 1.08
  global index 753/755 1.03 0.93 – 1.13
Cumulative follow-up
  coronary heart disease 363/393 0.94 0.82 – 1.09
  breast cancer 168/216 0.79 0.65 – 0.97
  global index 1374/1397 1.02 0.94 – 1.09
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 The global index 
 In statistical terms, there is no reason why HRs estimated for 
an array of outcomes cannot be synthesized, with appropriate 
weighting, to derive a summary HR estimate. What is at issue, 
however, is whether in epidemiological or clinical terms that 
estimate, designated as a  ‘ global index ’ , can be considered an 
interpretable indicator of overall benefi t or risk. 
 CHD, breast cancer, stroke, pulmonary embolism, colorec-
tal cancer, endometrial cancer, and hip fracture are dissimilar 
clinical and pathological entities, with different age distribu-
tions, geographic distributions, ethnic distributions, genetic 
determinants, environmental determinants, dosage and dura-
tion effects, and causes other than HT (some known, and 
some unknown). And as for all-cause mortality, there are as 
many determinants of increased or decreased risk as there are 
causes of death, or more. 
 It is absurd to propose that the HRs associated with such 
a widely heterogeneous array of outcomes and their determi-
nants can be synthesized to produce a single summary HR 
that indicates whether the overall benefi t of HT outweighs the 
risk, or vice versa. And, to the degree that it remains uncertain 
whether E   P or ET does or does not increase or decrease the 
risk of individual components of the global index, their inclu-
sion renders it all the more uninterpretable as a risk indicator. 
In addition, an incidence rate of an  ‘ index ’ has no discernible 
meaning. A consideration of benefi t and risk would be dif-
ferent, for example, for women with or without osteopenia, 
hypertension, hyperlipidemia, a family history of colorectal 
cancer, benign breast disease, or a previous history of venous 
thromboembolism. 
 The global index was also biased. An index was not speci-
fi ed a priori before the study commenced in 1993, and the 
protocol was fi rst modifi ed to include one in December 
1996 8,9 , 3 years after follow-up commenced. Formal moni-
toring began in 1997, and the index was again modifi ed in 
June 1997. In April 1998, after the fi rst analysis of the data 
had been conducted, it was once again modifi ed, and vertebral 
fractures were removed 8 . The effect of the removal was to bias 
the index: in the intervention phase, for vertebral fracture the 
 Table 2 Signifi cantly elevated/reduced hazard ratios for outcomes other than coronary heart disease and 
breast cancer included in the global index 
 Outcome  Exposed/controls  Hazard ratio  95% confi dence interval 
 E   P/placebo 8506/8102
Intervention phase
  stroke 159/109 1.37 1.07 – 1.76
  pulmonary embolism 87/41 1.98 1.36 – 2.87
  colorectal cancer 50/75 0.62 0.43 – 0.89
  hip fracture 53/75 0.67 0.47 – 0.95
Cumulative follow-up
  endometrial cancer 68/96 0.67 0.47 – 0.91
  hip fracture 212/270 0.81 0.68 – 0.97
 ET/placebo 5310/5429
Intervention phase
  stroke 169/130 1.35 1.07 – 1.70
  hip fracture 48/74 0.67 0.46 – 0.90
 E   P, estrogen plus progestogen therapy; ET, estrogen therapy 
 Table 3 Absolute risks per 10 000 women per year 
 Estrogen plus progestogen therapy  Estrogen therapy 
 Intervention phase  Cumulative follow-up  Intervention phase  Cumulative follow-up 
Coronary heart disease 6 3 3 4
Breast cancer 9 9 7 7
Stroke 9 5 11 5
Pulmonary embolism 9 4 4 4
Colorectal cancer 6 6 2 3
Endometrial cancer 1 3 NA NA
Hip fracture 6 5 6 2
All-cause mortality 1 1 3 1
Global index 20 12 4 1
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respective HRs among E   P and ET users were 0.68 (95% 
CI 0.48 – 0.96) and 0.64 (95% CI 0.44 – 0.93). In the cumula-
tive data, HRs for vertebral fracture were not given. The bias 
resulted in overestimation of the HR. 
 We turn next to the application of relevant causal principles 
to the WHI evidence. 
 Time order 
 At entry the women were screened for CHD and breast cancer, 
and, in respect of those endpoints the criterion of time order 
was satisfi ed. 
 Information bias 
 This was a prospective study, there was no misclassifi cation 
of the exposures, and there was no information bias. 
 Detection bias 
 At recruitment, the women were informed of a hypothesized 
reduced risk of CHD among HT users. In the intervention 
phase,  ‘ unblinding ’ was 6.9-fold more common among the 
E   P recipients than among the placebo recipients 
(44.4%/6.4%: see below). Awareness that this outcome was 
of interest could have resulted in overestimation of the mag-
nitude of the HRs for CHD among E   P users. 
 Among the E   P users, biased estimation of an elevated 
HR for breast cancer was inevitable since the women 
were informed of a hypothesized increase in the risk when 
recruited 3 , and, during the clinical trial, in the exposed 
and non-exposed women the respective  ‘ unblinding ’ rates, 
mainly because of vaginal bleeding, were 44.4% and 6.4%. 
Because of the differential  ‘ unblinding ’ rates, the HRs for 
CHD (see above), stroke and pulmonary embolism could 
also have been overestimated. In the cumulative data, fol-
lowing discontinuation of the use of E   P, after 13 years 
of follow-up, 7.2 years of which were  ‘ unblinded ’ , among 
100% of the participants knowledge of exposure status 
could further have biased the data. 
 By contrast, it is unlikely that the reduced HR estimates 
among E   P users for colorectal cancer, endometrial cancer, 
and hip fracture would also have been biased. If anything, 
detection bias would have tended to result in overestima-
tion of the HRs, not underestimation, and at recruitment the 
women were not alerted to possible risk reductions. 
 Among ET users, it is unlikely that the increased risk of 
stroke would have been due to detection bias. In the interven-
tion phase,  ‘ unblinding ’ occurred in    2% of the women 10 
because they were hysterectomized and bleeding did not 
occur. Nevertheless, the increased risk must be interpreted 
with caution (see: confounding; strength of association; 
statistical stability). 
 With regard to the reduced risks among ET users of breast 
cancer and hip fracture, detection bias, if present, would have 
resulted in overestimation of the risk, not underestimation. 
Again, however, the risk reductions must be cautiously inter-
preted (see: confounding; strength of association; statistical 
stability). 
 Confounding 
 For the E   P users, uncontrolled confounding could readily 
have explained the increased risks of CHD, breast cancer, 
stroke, and pulmonary embolism. Since the respective 
 ‘ unblinding ’ rates in the E   P and placebo recipients were 
44.4% and 6.4% 3 , it is likely that the differential knowledge 
of exposure status would have given rise not only to detection 
bias, but also to confounding. High rates of non-adherence to 
treatment (E   P, 42%; placebo, 38% 3 ) augmented that likeli-
hood; during follow-up, 10% of the placebo recipients 
switched to HT, which would further have augmented it: the 
reasons for stopping or switching (e.g. hyperlipidemia, benign 
breast disease, osteopenia, hypertension) could independently 
have been associated with one or more of the outcomes 
(e.g. CHD, breast cancer, hip fracture, stroke). 
 To reduce confounding due to non-adherence,  ‘ intention-
to-treat ’ analyses in which the HRs were estimated according 
to the initially assigned treatment, regardless of whether 
or not it was stopped, were used 10 . In trials in which non-
adherence rates are low (say,    10%), at the cost of somewhat 
attenuating the HRs,  ‘ intention-to-treat ’ analyses can reduce 
confounding. In the E   P trial, however, the non-adherence 
rates were exceptionally high, as was the  ‘ unblinding ’ rate 
(see: detection bias). In effect, both in the intervention and 
post-intervention phases the trial became an observational 
study. For that reason,  ‘ as treated ’ analyses, with full control 
for individual confounders, should have been performed. In 
addition, to minimize both detection bias and confounding, 
 ‘ as treated ’ analyses in women who remained  ‘ blinded ’ during 
the intervention phase should also have been performed 
(see: detection bias) 11 . And still further,  ‘ intention-to-treat ’ 
analysis would not have reduced confounding among women 
who switched their treatments. 
 In the post-intervention phase, almost 20% of the women 
did not consent for follow-up, and the reasons for refusal 
(e.g. chest pain, a suspicious breast lump, hypertension) could 
still further have confounded the comparisons. Moreover, 
following publication of the initial WHI fi ndings in 2002 3 , in 
the United States some 66% of menopausal women stopped 
using HT 12 ; in the WHI report, the magnitude of the decline 
in the use of E   P was not mentioned, but it would have been 
substantially greater than in the intervention phase. Thus, in 
the analysis of the cumulative data, the use of  ‘ intention-to-
treat ’ methods was indefensible. 
 By contrast, in the ET trial,    2% of the participants were 
 ‘ unblinded ’ 10 , and confounding (and detection bias) was less 
likely than in the E   P trial. Nevertheless, since 53.8% of 
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the placebo recipients switched to HT 10 , some degree of con-
founding was possible. Again, the use of  ‘ intention-to-treat ’ 
methods was not valid, and the increased risk of stroke could 
partly or wholly have been accounted for by confounding (see: 
strength of association). 
 Among the ET users, the risk reductions for breast cancer 
and hip fracture could also have been due to confounding. 
However, it is less likely that the reduced risk of breast cancer 
was confounded: in an earlier WHI report 13 , based on 10.7 
years of follow-up, in an  ‘ as treated ’ analysis of the combined 
intervention and post-intervention data, the HR for breast 
cancer was 0.68 (95% CI 0.49 – 0.95). 
 Strength of association 
 For the E   P and the ET recipients, all signifi cantly elevated 
HR estimates were    2.0 (Tables 1 and 2), and, with the single 
exception of pulmonary embolism (E   P: HR, 1.98; interven-
tion phase), they were    1.5. For such low estimates, particu-
larly HRs of    1.5, it is impossible to discriminate among 
bias, confounding and causation as alternative explanations 14 . 
In observational studies, causation can only confi dently be 
accepted if it is unlikely that bias or confounding can fully 
account for a substantially increased risk (say, a relative risk 
of    3.0). For example, among heavy smokers the risk of lung 
cancer is increased some 30-fold or more 15 . 
 Among the E   P users, the inverse values of the reduced 
HR estimates were 1.61 (1.00/0.62) for colorectal cancer, 1.49 
(1.00/0.67) for endometrial cancer, and 1.49 (1.00/0.67) for 
hip fracture, and the same considerations apply. And among 
the ET users, the respective inverse values for breast cancer 
and hip fracture were 1.27 (1.00/0.79) and 1.49 (1.00/0.67), 
and again the same considerations apply. 
 Statistical stability 
 Among the E   P recipients, for pulmonary embolism the 
lower 95% confi dence limit around the HR of 1.98 was 1.36 
(intervention phase), and the estimate was statistically stable. 
For the remaining signifi cantly elevated HRs, however, the 
lower 95% confi dence limits were 1.01 (breast cancer; inter-
vention phase), 1.11 (breast cancer; cumulative follow-up), 
1.07 (stroke; intervention phase), and 1.07 (stroke; cumula-
tive follow-up) (Tables 1 and 2). Thus, with the possible 
exception of pulmonary embolism, the signifi cantly elevated 
HRs were statistically unstable, and it would have taken mini-
mal detection bias or confounding to reduce the lower confi -
dence limits to    1.00. 
 With regard to the signifi cantly reduced HRs among the 
E   P recipients, the upper 95% confi dence limits were 0.89 
(colorectal cancer; intervention phase), 0.91 (endometrial can-
cer; cumulative follow-up), 0.95 (hip fracture; intervention 
phase), and 0.97 (hip fracture; cumulative follow-up). That is, 
the HR estimates for those outcomes were again statistically 
unstable, and it would have taken relatively little detection 
bias or confounding to increase the upper confi dence limits 
to    1.00. 
 Among the ET recipients, in the intervention phase, the 
lower 95% confi dence limit around the signifi cantly elevated 
HR for stroke was 1.07, and the upper limit for hip fracture 
was 0.90. Again, it would have taken minimal detection bias 
or confounding to nullify the statistical signifi cance of those 
associations. However, for breast cancer, since the respec-
tive upper confi dence limits around the HR of 0.79 were 
1.08 (intervention phase) and 0.97 (cumulative follow-up) 
(Table 1), the evidence to suggest no increase in the risk was 
statistically robust.  
 Duration – response effects 
 In the WHI report 1 , duration of use of E   P or ET was not 
mentioned, but in the intervention phases the discontinuation 
rates ranged from 38% 3 to 53.8% 10 , and the average dura-
tions of use would have been substantially less than 5.6 years 
(E    P) or 7.2 years (ET). In addition, since most of the women 
stopped using HT soon after the E   P trial ended, in the 
cumulative data the average durations of use would have been 
substantially less than 13 years. For those reasons, duration – 
response effects cannot be evaluated. 
 Internal consistency 
 In published WHI reports, the results for the primary out-
comes have been inconsistent. For CHD, among the E   P 
recipients, in the initial report (2002) 3 the HR was 1.29 (95% 
CI 1.02 – 1.63) after a mean of 5.2 years of follow-up; yet, 
after the same duration of follow-up, when what were repre-
sented as the  ‘ fi nal results ’ were published (2003) 16 , the HR 
was 1.24 (95% CI 1.00 – 1.54). And after 5.6 years 1 of fol-
low-up (intervention phase), the HR was 1.18 (95% CI 0.95 –
 1.45) (Table 1). That is, over an interval of an additional 0.4 
years (5.6 – 5.2) of follow-up, inconsistent but  ‘ statistically 
signifi cant ’ HRs of 1.29 and 1.24 changed to a  ‘ non-signifi cant ’ 
value of 1.18, and after 13 years of follow-up to 1.09 
(0.96 – 1.24) (Table 1). 
 The WHI investigators stated that  ‘ some HRs differ slightly 
from those previously reported due to the more complete 
outcome ascertainment in the present report’ 1 . However, the 
shift from statistical signifi cance 3,16 to non-signifi cance 1 was 
not  ‘ slight ’ : in the initial WHI publication 3 , it was stated that 
the HR of 1.29  ‘ [reached] nominal statistical signifi cance ’ , 
and that  ‘ a suffi cient number of CHD events had occurred 
by 5.2 years of follow-up to suggest that continuation to the 
planned end would have been unlikely to yield a favorable 
result ’ . The initially reported increased risk of CHD among 
E   P recipients, not subsequently confi rmed, had a major 
public health impact. 
 For breast cancer, in a previous WHI report 17 ,  ‘ the increased 
risk of breast cancer associated with the use of [E    P] declined 
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a decline was not evident after 13 years of follow-up 1 when 
the majority of the women would have discontinued the use 
of HT years previously: the respective HRs in the interven-
tion phase and in the cumulative follow-up data were 1.24 
and 1.28 (Table 1). 
 The designation of breast cancer as an endpoint also 
changed in the course of the study. In the original protocol 18 , 
it was listed as a secondary outcome. Among the secondary 
outcomes, breast cancer was then designated as the primary 
adverse outcome 8 . Then, in the WHI report 1 , together with 
CHD, breast cancer was designated as a primary endpoint. 
The shifts in the designation from a secondary outcome, to 
a primary adverse outcome, and then to a primary endpoint 
were not explained. Had breast cancer remained a secondary 
outcome as originally specifi ed, the adjusted lower 95% con-
fi dence limit around the initially reported HR of 1.26 would 
have been 0.83 3 , and the association could have been due to 
chance (see: statistical stability). 
 External consistency 
 In the Collaborative Reanalysis 19 , among current users of HT 
an increased relative risk of breast cancer declined to baseline 
within 5 years of stopping; in the Million Women Study 20 , the 
increased risk among HT users declined within 2 years. Yet, 
in the WHI study, the HR for E   P users remained elevated 
after 13 years of follow-up, when the majority of the women 
had stopped using HT years earlier. 
 In the Collaborative Reanalysis 19 and Million Women 
Study 20 , the relative risks for breast cancer were elevated for 
ET users; in the WHI 1 , the HRs were reduced. 
 With regard to CHD, the preponderance of the evidence 
from observational studies 21,22 suggests that HT reduces the 
risk, perhaps most markedly in recently menopausal women. 
Yet, in the WHI study, a risk reduction was not evident 
(see: detection bias). 
 Biological plausibility 
 HT has benefi cial effects on many metabolic and vascular risk 
factors 22 , and a reduced risk of CHD, although biologically 
plausible, was not observed in the WHI study, possibly because 
of detection bias. 
 With regard to the risk of breast cancer among E   P users, 
some mechanisms may increase it, and other mechanisms 
may decrease it 23,24 . However, based on the doubling times 
for the multiplication of malignant cells, it takes at least 
10 years for breast cancer to become clinically evident, and 
among E   P users the increased risk in the intervention 
phase was biologically implausible. For the risk reduction 
among ET users, since some mechanisms may reduce the 
risk, while other mechanisms may increase it 23,24 , biological 
plausibility cannot be assessed. 
 With regard to stroke and venous thromboembolism, among 
women of child-bearing age, the use of oral contraceptives 
increases the risks 25 , and it is plausible that HT may have the 
same effects in menopausal women. 
 With regard to hip fracture, HT has benefi cial effects on 
menopausal bone loss 26 , and a risk reduction is plausible. 
 CONCLUSIONS 
 With regard to CHD, earlier observational and experimental 
studies 21,22 raised the possibility that HT may reduce the risk. 
The original protocol-specifi ed aim in the WHI study 18 was 
to evaluate that possibility and, surprisingly, in the initial WHI 
report 3 it was instead claimed that E   P increases it. Based on 
the total evidence, however, the initial claim has not been 
confi rmed, and the WHI study has not established that E   P 
increases the risk of CHD; nor has it ruled out the possibility 
that HT may even reduce the risk. 
 The increased risk of breast cancer observed among E   P 
users did not satisfy the criteria of detection bias, confound-
ing, strength of association, statistical stability, internal con-
sistency, external consistency, and biological plausibility. E   P 
may or may not increase the risk of breast cancer, but the WHI 
fi ndings did not establish that it does. 
 For ET users, the data were suffi ciently stable statistically 
to rule out an increased risk of breast cancer. It is even pos-
sible that ET reduces the risk, but the evidence to support 
that possibility was statistically unstable, and it needs to be 
independently confi rmed. 
 With regard to the increased risk of stroke among E   P and 
ET users, evidence from studies of oral contraceptive use 25 
supports the possibility of some increase in the risk, some 
limitations to the causal criteria in the WHI study notwith-
standing. However, the increased risk needs to be indepen-
dently confi rmed. For pulmonary embolism, the association 
was statistically robust and consistent with other evidence 25 . 
 With regard to the decreased risks of colorectal and endo-
metrial cancer in E   P users, the fi ndings are credible 27 , 
although statistically borderline. Again, the risk reductions 
need to be independently confi rmed. 
 With regard to hip fracture, the decreased risks are again 
credible 26 . In addition, in the intervention phase, the risks of 
vertebral fracture (E   P: HR 0.68, 95% CI 0.48 – 0.96; ET: 
HR 0.64, 95% CI 0.44 – 0.93), and of all fractures (E   P: HR 
0.76, 95% CI 0.69 – 0.83; ET: HR 0.72, 95% CI 0.64 – 0.80) 
were also reduced 1 , adding further to the credibility of the 
evidence. Again, however, the risk reductions need to be inde-
pendently confi rmed. 
 If, despite the limitations of the WHI study, causality (or 
protection) is assumed, and the  ‘ worst case ’ assumption is 
made that all the elevated HRs were causal, and the  ‘ best 
case ’ assumption is made that all reduced HRs were protec-
tive, what are the public health implications? For the primary 
endpoints, and the endpoints included in the global index, 
the absolute risks ranged from 7 per 10 000 women per 
year (breast cancer in ET users) to 11 per 10 000 women 
per year (stroke in ET users) (Table 3). Or put another way, 
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stroke, pulmonary embolism, colorectal cancer, hip fracture, 
or all-cause mortality attributable to the use of HT would 
have been minor. 
 For the global index, the absolute risks, ranging from 1 to 
20 per 10 000 women per year (Table 3), must be disregarded 
since, in epidemiological and clinical terms, a synthesized 
summary estimate of benefi t and risk is uninterpretable. That 
index was a  post hoc invention of the WHI investigators, and 
the selection of the included components, one of which was 
subsequently removed, was also biased. 
 Possible benefi t versus risk needs to be separately assessed 
for each particular population and outcome under study, 
and women with menopausal symptoms, osteoporosis, or 
a family history of colorectal cancer benefi t from the use 
of E   P; E   P users are also at reduced risk of endome-
trial cancer. Hysterectomized women benefi t from the use 
of ET, and the WHI fi ndings now raise the possibility that 
ET may reduce the risk of breast cancer. In addition, the 
preponderance of the epidemiological evidence suggests that 
recently menopausal women who use HT are at reduced risk 
of CHD 21,22 . 
 Finally, hormones other than conjugated equine estrogen 
and medroxyprogesterone acetate were not evaluated in the 
WHI study, as has been acknowledged by the investigators. 
The products currently in use have different biological effects 
and are prescribed in low doses 28 . For these reasons, further 
studies are needed. 
 We conclude that over-interpretation and misrepresentation 
of the fi ndings in the WHI study have resulted in major dam-
age to the health and well-being of menopausal women. The 
WHI was not  ‘ a victory for women and their health’ 2 , and the 
claim that the fi ndings  ‘ do not support the use of this therapy 
for chronic disease prevention’ 1 is not defensible. Nor can the 
pejorative editorial statement that  ‘ the WHI overturned medi-
cal dogma regarding menopausal [HT] ‘ 2 be defended. 
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